These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. PPARγ activation improves the microenvironment of perivascular adipose tissue and attenuates aortic stiffening in obesity. Chen JY; Wu YP; Li CY; Jheng HF; Kao LZ; Yang CC; Leu SY; Lien IC; Weng WT; Tai HC; Chiou YW; Tang MJ; Tsai PJ; Tsai YS J Biomed Sci; 2021 Mar; 28(1):22. PubMed ID: 33781257 [TBL] [Abstract][Full Text] [Related]
4. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis. Caglayan E; Stauber B; Collins AR; Lyon CJ; Yin F; Liu J; Rosenkranz S; Erdmann E; Peterson LE; Ross RS; Tangirala RK; Hsueh WA Diabetes; 2008 Sep; 57(9):2470-9. PubMed ID: 18511847 [TBL] [Abstract][Full Text] [Related]
5. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Matsui J; Terauchi Y; Kubota N; Takamoto I; Eto K; Yamashita T; Komeda K; Yamauchi T; Kamon J; Kita S; Noda M; Kadowaki T Diabetes; 2004 Nov; 53(11):2844-54. PubMed ID: 15504964 [TBL] [Abstract][Full Text] [Related]
6. The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes. Zhao Q; Wu X; Yan S; Xie X; Fan Y; Zhang J; Peng C; You Z J Neuroinflammation; 2016 Oct; 13(1):259. PubMed ID: 27716270 [TBL] [Abstract][Full Text] [Related]
7. Augmented bacterial elimination by Kupffer cells after IL-18 pretreatment via IFN-γ produced from NK cells in burn-injured mice. Miyazaki H; Kinoshita M; Ono S; Nakashima M; Hara E; Ohno H; Seki S; Saitoh D Burns; 2011 Nov; 37(7):1208-15. PubMed ID: 21696891 [TBL] [Abstract][Full Text] [Related]
8. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575 [TBL] [Abstract][Full Text] [Related]
9. The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves nitric oxide availability, renin-angiotensin system and aberrant redox regulation in the kidney of pre-hypertensive rats. Kvandova M; Barancik M; Balis P; Puzserova A; Majzunova M; Dovinova I J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29980143 [TBL] [Abstract][Full Text] [Related]
10. Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats. Cao Z; Ye P; Long C; Chen K; Li X; Wang H Pharmacology; 2007; 79(3):184-92. PubMed ID: 17356310 [TBL] [Abstract][Full Text] [Related]
11. Protective Role of Peroxisome Proliferator-Activated Receptor-γ in the Development of Intracranial Aneurysm Rupture. Shimada K; Furukawa H; Wada K; Korai M; Wei Y; Tada Y; Kuwabara A; Shikata F; Kitazato KT; Nagahiro S; Lawton MT; Hashimoto T Stroke; 2015 Jun; 46(6):1664-72. PubMed ID: 25931465 [TBL] [Abstract][Full Text] [Related]
12. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}. Subramanian V; Golledge J; Ijaz T; Bruemmer D; Daugherty A Circ Res; 2010 Oct; 107(8):953-8. PubMed ID: 20798360 [TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma targeting nanomedicine promotes cardiac healing after acute myocardial infarction by skewing monocyte/macrophage polarization in preclinical animal models. Tokutome M; Matoba T; Nakano Y; Okahara A; Fujiwara M; Koga JI; Nakano K; Tsutsui H; Egashira K Cardiovasc Res; 2019 Feb; 115(2):419-431. PubMed ID: 30084995 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Grommes C; Landreth GE; Sastre M; Beck M; Feinstein DL; Jacobs AH; Schlegel U; Heneka MT Mol Pharmacol; 2006 Nov; 70(5):1524-33. PubMed ID: 16887936 [TBL] [Abstract][Full Text] [Related]